Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASIK with Cross-linking for Hyperopia
NCT01893359Phase 2Terminated
- Sponsor
- Glaukos Corporation
- Start
- Aug 2013
- Primary completion
- Feb 2015
- Modality
- Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Flavin mononucleotide in Hyperopia and hyperopic astigmatism (3 arms), sponsored by Glaukos Corporation. Primary endpoint: Manifest Refraction Spherical Equivalent Regression at 6 months. Started Aug 2013; status: terminated.
02
Drugs
Flavin mononucleotide
03
Conditions
Hyperopiahyperopic astigmatism
Beyond the preview
Go deeper on NCT01893359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893359.